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Abstract. The majority of ovarian cancer patients with 
advanced disease at diagnosis will relapse following primary 
treatment, with a dismal prognosis. Monitoring the levels of 
serum markers in patients under follow-up may be essential for 
the early detection of relapse, and for distinguishing high-risk 
patients from those with less aggressive disease. The aim of 
the present study was to investigate the possible predictive 
value of human epididymis protein 4 (HE4) and carbohydrate 
antigen 125 (CA125) in relation to recurrence of epithelial 
ovarian cancer by measuring the two markers during follow-up 
subsequent to surgery and adjuvant first‑line carboplatin/pacli-
taxel chemotherapy. Serum HE4 and CA125 were analyzed in 
88 epithelial ovarian cancer patients at the end of treatment and 
consecutively during follow-up. The patients were divided into 
a high-risk and a low-risk group based on having an increase in 
HE4 and CA125 levels above or below 50% during follow-up, 
relative to the baseline (end-of-treatment) level. Disease recur-
rence was detected in 55 patients during follow-up. Patients 
with an increase in HE4 of >50% at 3- and 6-month follow-up 
compared to the end-of-treatment sample had significantly 
poorer progression-free survival (PFS) [hazard ratio (HR), 2.82 
(95% CI, 0.91-8.79; P=0.0052) and HR, 7.71 (95% CI, 
3.03-19.58; P<0.0001), respectively]. The corresponding 3- and 
6-month biomarker assessments for increased CA125 levels 
(>50%) showed HRs of 1.86 (95% CI, 0.90-3.80; P=0.0512) and 
2.55 (95% CI, 1.39-4.68; P=0.0011), respectively. Multivariate 
analysis confirmed HE4 as a predictor of short PFS, with an HR 
of 8.23 (95% CI, 3.28-20.9; P<0.0001) at 6-month follow-up. 
The increase of CA125 was not a significant prognostic factor 
in multivariate analysis for PFS. In conclusion, HE4 appears 
to be a sensitive marker of recurrence and instrumental in risk 
assessment during the first 6 months of follow‑up.
Introduction
The majority of patients with advanced ovarian cancer will 
experience disease recurrence within a few years from the 
time of diagnosis (1). Due to the nature of the disease, with its 
location in the small pelvis and spread in the form of diffuse 
carcinosis, there are no reliable methods of detecting early 
recurrence using ultrasound, computed tomography (CT) or 
magnetic resonance imaging (2,3). Furthermore, it is well 
known that serum levels of carbohydrate antigen 125 (CA125) 
have a considerable lead-time before clinically detectable 
recurrence (4,5).
Currently, the clinical consequence of rising CA125 levels 
remains an issue of great debate, particularly as to whether 
re-treatment should be initiated based only on biochemical 
CA125 recurrence. Rustin et al (6) demonstrated that survival 
time was not improved when treatment was based on biochem-
ical recurrence alone. However, it should be noted that this 
study investigated only women who experienced normalization 
of CA125 during their first‑line treatment. Furthermore, the 
study has been criticized for its very diverse relapse treatment, 
including different chemotherapy regimens, which may not 
have been in accordance with the current standard. Also, none 
of the patients were offered secondary cytoreductive surgery 
that may have led to improved survival; this issue is currently 
under intense discussion in the scientific community, and the 
results of the ongoing randomized DESKTOP III (7) study 
are eagerly awaited to clarify whether surgery for relapse will 
improve the outcome for patients with recurrent disease. It may 
be highly relevant to practice active monitoring of women after 
the end of treatment to detect recurrence as early as possible, 
particularly if the DESKTOP III study demonstrates a survival 
benefit. Furthermore, a retrospective study by Fleming et al (8) 
indicated that each week delay of treatment following the first 
CA125 elevation in recurrent ovarian cancer correlated with 
a 3% increased chance of suboptimal resection at secondary 
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cytoreductive surgery, and therefore CA125 surveillance 
increased optimal resectability at secondary cytoreductive 
surgery. Thus, the current situation calls for better methods for 
early detection of recurrence with the perspective of curatively 
intended surgical and/or non-surgical treatment. CA125 is 
insufficient for a number of reasons, including the fact that it 
is not always elevated in patients with mucinous tumors (9).
Human epididymis protein 4 (HE4) is a relatively new 
biomarker approved by the United States Food and Drug 
Administration (FDA) for monitoring of patients with 
epithelial ovarian cancer. HE4 is encoded by the WFDC2 
gene located on chromosome 20q12-13.1 (10) and belongs to 
the family of whey‑acidic four‑disulfide core proteins with 
suspected trypsin-inhibitor properties (11). However, the 
biological role of HE4 has not yet been identified (12). HE4 
is upregulated in ovarian cancer compared to other types of 
carcinomas and benign ovarian tumors (13,14). Recent studies 
have identified HE4 as a complementary marker for ovarian 
cancer that can be elevated in some cases where CA125 is 
not (15-21); however, its potential value in the early detection 
of recurrence has not been elucidated.
The aim of the present study was to explore the clinical 
value of serial measurements of HE4 and CA125 during 
follow-up for the early detection of recurrence, and the addi-
tive value of combining the two markers.
Materials and methods
Study population. The current study included patients with 
ovarian cancer who had completed first-line combination 
chemotherapy with paclitaxel (175 mg/m2 intravenously) and 
carboplatin (AUC=5) every 3 weeks at two Danish Hospitals 
(Aalborg University Hospital, Aalborg, Denmark; and Vejle 
Hospital, Vejle, Demark) and attended follow-up according 
to national guidelines. Patients with a serum sample drawn 
at the end of chemotherapy and ≥2 post-chemotherapy blood 
samples were included in the study.
All patients were entered as part of a translational research 
protocol, with peripheral venous blood samples drawn at the 
end of chemotherapy and at every scheduled follow-up visit: 
Every 3 months for the first two years, every 6 months for the 
third year, and once a year for the fourth and fifth years. Clin-
ical data were recorded in detailed case report forms. Detailed 
patient characteristics have been given elsewhere (22).
The study was carried out in compliance with the Helsinki II 
Declaration (23) and all patients signed an informed consent 
form. The Danish Biomedical Research Ethics Committee 
and the Danish Data Protection Agency approved the study 
according to Danish law. Recurrence of disease was defined 
according to the Gynecological Cancer Intergroup CA125 
criteria (24,25) and/or radiological confirmation of tumor 
recurrence, whichever occurred first. Biochemical recurrence 
detected by CA125 required CT confirmation to verify the 
diagnosis of recurrence.
Serum CA125 assay. The quantitative levels of serum 
CA125 were determined using the commercially available 
CanAg CA125 Enzyme Immunometric Assay (EIA) kit (cat. 
no.,400-10; Fujirebio Diagnostics AB, Gothenburg, Sweden) 
with inter‑ and intra‑assay coefficients of variation (CV) of 
≤10% and a sensitivity of 1.5 IU/ml. The assay is based on 
a direct sandwich technique using two mouse monoclonal 
antibodies, Ov197 and Ov185, directed against two indepen-
dent epitopes of the protein core of the CA125 antigen. The 
analysis was performed in 25 µl of serum and followed the 
manufacturer's protocol.
Serum HE4 assay. HE4 serum levels were determined by 
the enzyme-linked immunosorbent assay technique using a 
commercially available FDA-approved kit (HE4 EIA kit, cat.
no., 404-10; Fujirebio Diagnostics AB). The analysis used 
25 µl serum; the analytical steps were conducted according 
to the manufacturer's instructions and have been described in 
further detail in a previous publication from our group (21).
HE4 control 1 and 2 were used for validation of each assay 
series. The lyophilized controls contained HE4 antigen in a 
human serum matrix and a non-azide antimicrobial preserva-
tive included in the kit. The mean values of control duplicates 
and the duplicate replicates of calibrators A-F were within the 
specified ranges provided by the manufacturer for all runs. 
The total CV in the present analysis was between 3.3 and 8.8% 
in the high and low range of HE4 levels, respectively.
Statistical analyses. A validated HE4 threshold for monitoring 
during follow-up has not been established, and the current 
study aimed to investigate changes in HE4 and CA125 during 
follow-up compared to their ‘baseline’ level at the end of adju-
vant chemotherapy treatment. At 3- and 6-month follow-up 
examinations, the HE4 and CA125 levels were compared to 
the baseline end-of-treatment (EOT) sample, and patients 
were divided into groups based on having an increase above 
or below/equal to 50%. From this dichotomous classification, 
a univariate Kaplan-Meier log-rank analysis was performed 
to assess the association with progression-free survival (PFS).
Multivariate analysis (Cox regression) was conducted for 
the identification of independent factors predicting PFS.
The study also aimed to investigate whether the EOT sample 
drawn at the end of chemotherapy (corresponding to the begin-
ning of follow-up) was able to predict disease recurrence at this 
very early time point. It was decided a priori that the data would 
be analyzed at a set sensitivity of 90% since the aim was to 
investigate whether the markers were sensitive enough to detect 
relapse from a serum sample taken just before the follow-up. A 
sensitivity of 90% for detecting recurrence was achieved when 
the threshold was 41 pmol/l for HE4, and 1 U/ml for CA125. The 
latter, which is the lowest detectable level, was not meaningful 
in the analysis of specificity, positive predictive value (PPV) or 
negative predictive value (NPV) for CA125.
For the analysis of HE4 and CA125 thresholds, simple and 
multiple regression analyses were used. Statistical analyses 
were performed with NCSS software (version 2007; NCSS, 
Kaysville, UT, USA; www.ncss.com) and STATA 13.1 
(College Station, TX, USA). The Mann-Whitney U test was 
used for the comparison of medians. P<0.05 was considered to 
indicate statistically significant differences. 
Results
Patient characteristics. From May 2006 through August 
2011, a total of 283 consecutive patients were enrolled in the 
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translational research protocol, and all had serum samples 
drawn during chemotherapy. In July 2008, the protocol was 
amended and approved for collection of blood samples during 
follow‑up, and 88 patients were identified as having a serum 
EOT sample and ≥2 sequential samples collected during the 
follow-up period, according to the inclusion criteria. The 
median follow-up time for patients still alive (n=52) was 
47 months (range, 26-86 months). Of the 88 patients, 55 were 
diagnosed with recurrence and 38 patients died during 
follow‑up. More than 97.7% had ≥3 serial serum samples, 
and 72.7% had ≥4 serial samples (maximum, 12). The median 
time between collection of the EOT sample and the first 
follow-up sample at 3 months was 93 days (31-147 days) and 
the median time to the sample drawn at 6-month follow-up 
was 187.5 days (68-266 days). In total, 547 serum samples 
were analyzed: 83 EOT samples and 464 samples during 
the subsequent follow-up period. Patient characteristics are 
presented in Table I.
Prediction of relapse from EOT samples by CA125, HE4 and 
combined CA125/HE4 levels. The median CA125 serum level 
at the end of first‑line chemotherapy treatment (prior to the 
initiation of follow-up) was 4 U/ml (95% CI, 1-5 U/ml; range 
1-14 U/ml) for patients without relapse and 5 U/ml (95% 
CI, 3-7 U/ml; range 1-116 U/ml) for patients with relapse 
(P=0.0985, Mann-Whitney U test).
The median HE4 serum level at the end of first‑line chemo-
therapy treatment (prior to the initiation of follow-up) was 
51 pmol/l (95% CI, 46-59 pmol/l; range, 15-127 pmol/l) for 
patients without relapse and 67 pmol/l (95% CI, 60-81 pmol/l; 
range, 31-229 pmol/l) for patients with relapse (P=0.0013, 
Mann-Whitney U test).
Fig. 1 illustrates the receiver operating characteristic curve 
analysis for samples collected at the end of first‑line treatment 
prior to follow-up (EOT sample), and prediction of recurrence 
with relapse (PFS) as the endpoint.
HE4 values at the end of first-line treatment classified 
70 patients (84.3%) as being in the high risk of relapse group, 
and 13 (15.7%) into the low-risk group, with a sensitivity of 
90.0% (95% CI, 79.0‑96.8%), a specificity of 25.8% (95% CI, 
11.9-44.6%), a PPV of 67.1% (95% CI, 54.9-77.9%) and an 
NPV of 61.5% (95% CI, 31.6-86.1%) (data not shown).
Table I. Patient characteristics (n=88).
Clinicopathological parameter Value
Age, years
  Median 64.0
  Range 28-77
FIGO stage, n (%)
  I 22 (25.0)
  II 7 (8.0)
  III 44 (50.0)
  IV 15 (17.0)
Gradea, n (%)
  1 11 (16.9)
  2 25 (38.5)
  3 29 (44.6)
Histological type, n (%)
  Serous 65 (73.9)
  Mucinous 4 (4.5)
  Endometrioid   9 (10.2)
  Clear cell 6 (6.8)
  Otherb 4 (4.5)
Residual tumor, n (%)
  0 cm 56 (63.6)
  <1 cm 11 (12.5)
  ≥1 cm 21 (23.9)
an=65 (23 patients not graded, e.g. clear cell, carcinosarcoma or biopsy 
only); bcarcinosarcoma, undifferentiated, transitiocellular, mixed or 
carcinoma not further classified. FIGO, International Federation of 
Gynecology and Obstetrics.
 
Figure 1. ROC curves for women with ovarian cancer with relapse as the end-
point. Risk stratification was performed using blood sample drawn at the end 
of first line adjuvant treatment prior to follow‑up. (A) CA125, (B) HE4 and 
(C) combined HE4 and CA125 at the end of treatment for cases (relapse) vs. 
patients with no relapse during follow-up. ROC, receiver operating character-
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When combining HE4 and CA125, 69 patients (83.1%) 
were in the high-risk and 14 (16.9%) in the low-risk group, 
resulting in a sensitivity of 90.0% (95% CI, 79.0-96.8%), a 
specificity of 29% (95% CI, 14.2‑48.0%), a PPV of 68.1% (95% 
CI, 55.8-78.8%) and an NPV of 64.3% (95% CI, 35.1-87.2%) 
(data not shown).
Prediction of relapse during follow‑up. Fig. 2 (patients 
without relapse) and Fig. 3 (patients with relapse) illustrate 
selected cases during the follow‑up process, in which the first 
serum sample is the EOT sample and subsequent samples were 
obtained during the follow-up visits. Analysis of HE4 and 
CA125 levels at 3 months after EOT (Fig. 4A and B) revealed 
that an increase of ≥50% (high-risk patients) relative to the 
level at EOT is associated with a significant worsening of 
PFS. In particular, a HE4 increase >50% was correlated with 
significant worsening of PFS time [hazard ratio (HR), 2.82; 
95% CI, 0.91-8.79; P=0.0052, log-rank test]. Additionally, 
increased CA125 (>50%) was associated with poorer PFS time 
(HR, 1.86; 95% CI, 0.90-3.80; P=0.0487, log-rank test).
The median PFS was 25.1 months (95% CI, 17.7-56.8) if 
HE4 did not increase >50% compared to the EOT sample, 
while it was 11.1 months (95% CI, 11.0-12.4) for an increase 
>50% at the 3-month follow-up.
For CA125 at 3 months, the median PFS was 28.7 months 
(95% CI, 17.4-56.8) if stable, and 13.4 months (95% CI, 
11.5-24.9) if increased >50%.
The impact of increased HE4 became more clear after 
6 months of follow-up (HR, 7.71; 95% CI, 3.03-19.58; P<0.0001, 
log-rank test) (Fig. 4D and E), with a median PFS time of 
56.8 months (95% CI, 28.7-63.2) if stable, compared with 
11.4 months (95% CI, 10.8-12.1) when HE4 increased >50%. 
The corresponding median PFS values were 56.8 months (95% 
CI, 28.7-63.2) vs. 14.2 months (95% CI, 12.0-7.4) for CA125 
(HR, 2.55; 95% CI, 1.39-4.68, P=0.0011, log-rank test).
Combining the two markers and classifying the patients 
into a high-risk group if both markers had increased >50% 
revealed similar results: P<0.0001 with a median PFS of 
25.1 months (95% CI, 17.7-56.8) if both markers were stable, 
and 11.5 months (95% CI, 9.2-11.6) if both markers increased 
Figure 2. Graphs showing the development (in percentage compared to the end-of-treatment sample) of CA125 and HE4 levels during follow-up for selected 
patients without disease relapse during follow-up. aId 188 with HE4 levels of 100-150 pmol/l during follow-up was diagnosed with a metastasizing pancreatic 
tumor at 16-month follow-up. bId 233 only had increased HE4 shortly after the end of chemotherapy treatment, which dropped to within the normal range 
during follow-up. cId 249 was diagnosed with a new primary tumor (a lung adenocarcinoma) at the time of increasing HE4; HE4 increased from 102 to 
376 pmol/l in 3 months just prior to the lung cancer diagnosis. dId 272 had HE4 >150 pmol/l without clinical signs of relapse. HE4, human epididymis 
protein 4; CA125, carbohydrate antigen 125.
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Figure 3. Graphs showing the development (in percentage compared to the end-of-treatment sample) of CA125 and HE4 levels during follow-up for selected 
patients with progressive disease/relapse during follow-up. The vertical line illustrates the time of relapse. HE4, human epididymis protein 4; CA125, 
carbohydrate antigen 125.
Figure 4. Kaplan-Meier curves for progression-free survival analysis for samples analyzed at (A-C) 3-month and (D-F) 6-month follow-up. Low risk indicates 
no increase in marker compared to the end‑of‑treatment sample; high risk indicates an increase in marker of ≥50% compared to the end‑of‑treatment sample. 
HE4, human epididymis protein 4; CA125, carbohydrate antigen 125.
  A   B   C
  D   E   F
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≥50% at 3 months (Fig. 4C). However, this group of high‑risk 
patients was small at the 3-month follow-up (n=7). At 
6 months, the combination of both markers also predicted PFS 
P<0.0001 (Fig. 4F), with a median PFS of 56.8 months (95% 
CI, 28.7-63.2) if both markers were stable, and 11.4 months 
(95% CI, 10.9‑11.9) if both markers increased ≥50%.
On multivariate analysis, CA125 was non-significant at 
3‑ and 6‑month follow‑up, while HE4 was highly significant 
at 6-month follow-up, with an HR of 8.23 (95% CI, 3.28-20.9; 
P<0.0001, Cox regression) (Table II). For the combination of 
HE4 and CA125 on multivariate analysis, there were too few 
high-risk patients (n=7) with both markers positive at 3 months 
for the analysis to be conducted; whereas the HR at 6 months 
was 7.43 (95% CI, 2.92-18.9; P<0.0001) (data not shown) when 
both biomarkers increased ≥50%.
Discussion
In June 2008, the HE4 EIA kit (Fujirebio Diagnostics AB) 
was approved by the FDA to monitor recurrence or progres-
sive disease in patients with epithelial ovarian cancer. In 
September 2011, the FDA approved marketing of the HE4 test 
(Fujirebio Diagnostics, Malvern, Pennsylvania) in combina-
tion with the CA125 test in the Risk of Ovarian Malignancy 
Algorithm (ROMA™) as a diagnostic tool for determining 
the likelihood of malignancy at the time of surgery in women 
presenting with an ovarian adnexal mass. ROMA™ is a 
qualitative serum test that combines the results of HE4 EIA, 
ARCHITECT CA125 II™ (not the same CA125 test used by 
the present study) and menopausal status into a numerical 
value and classifies women as being at low‑ or high‑risk for 
malignant disease. This risk is given as an adjunct to the two 
test results for CA125 and HE4.
Another possible application of HE4 is during follow-up, 
which has only been sparsely investigated (26-31). A simple 
approach is to analyze the marker at the EOT in an effort to 
identify a group of patients at high risk of early recurrence, 
an important aspect prompting for further investigation. The 
results presented herein indicate that analyzing HE4 at this 
stage is insufficient for reliable classification with regard to the 
risk of recurrence.
In the current study, measurements of HE4 at the 3- and 
6-month follow-ups demonstrated a significant difference 
in PFS compared with CA125, with considerably higher 
hazard ratios for HE4. Combination of the two markers, with 
classification of the patients into a high‑risk group if both 
markers increased ≥50%, did not provide additional value. 
By reviewing the Kaplan-Meier curves, it appears that HE4 
Table II. Multivariate progression-free survival analysis for 3 and 6 months of follow-up.
 3-month follow-up 6-month follow-up
 ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
Variable HR 95% CI P-value HR 95% CI P-value
Age 0.97 0.94-1.00 0.081 0.96 0.93-1.00 0.034
FIGO stage
  I/II 1.00  Ref  1.00  Ref
  III/IV 9.99 2.70-36.9 <0.001 5.90 1.89-18.4 0.002
Tumor grade 
  1 1.00  Ref 1.00  Ref
  2/3/not graded 2.54 0.86-7.71 0.093 1.42 0.48-4.15 0.524
Histology
  Serous 1.00  Ref 1.00  Ref
  Non-serousa  1.33 0.52-3.40 0.546 1.12 0.44-2.85 0.816
Residual tumor
  0 cm 1.00  Ref 1.00  Ref
  <1 cm 3.88 1.50-10.0 0.005 2.06 0.84-5.02 0.112
  ≥1 cm 2.17 0.92‑5.11 0.078 2.24 0.94‑5.35 0.069
HE4
  Below cut-off 1.00  Ref 1.00  Ref
  Above cut-off 1.31 0.46-3.72 0.612 8.28 3.28-20.9 <0.0001
CA125 
  Below cut-off  1.00  Ref 1.00  Ref
  Above cut-off 1.29 0.60-2.76 0.513 1.45 0.67-3.17 0.348
aMucinous, endometrioid, clear cell and other. FIGO stage was divided into stage I/II vs. stage III/IV, grade was divided into grade 1 vs. grade 
2/3/not graded, and histology into serous vs. non-serous to avoid too many parameters being entered into the Cox model in relation to the 
number of events. FIGO, International Federation of Gynecology and Obstetrics; HE4, human epididymis protein 4; CA125, carbohydrate 
antigen 125; HR, hazard ratio; CI, confidence interval; Ref, reference.
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levels are responsible for delineating the large difference in 
PFS. This was also found to be true on multivariate analysis: 
CA125 proved not to be significant at 3‑ or 6-month follow-up, 
whereas HE4 was highly significant at 6‑month follow‑up with 
an HR of 8.23. Similarly, combining HE4 and CA125 in the 
multivariate analysis, HE4 was revealed to be the important 
marker, while CA125 appeared not to complement the prog-
nostic value of HE4 during follow-up.
A study by Havrilesky et al (26) monitored 27 patients 
with advanced ovarian cancer subsequent to chemotherapy 
and evaluated a biomarker panel of which HE4 was one. All 
27 patients experienced recurrence following initial response 
to treatment. The sensitivity for predicting recurrence was 
100% for the biomarker panel and 96% for CA125. In 15 
patients (56%), ≥1 panel biomarkers were elevated earlier 
(range, 6-69 weeks) than CA125 and prior to other clinical 
evidence of recurrence. However, a drawback of this study is 
the lack of a control group to enable comparison of marker 
behavior during follow-up in patients with and without recur-
rence. The current study also demonstrated that, compared to 
CA125, more patients had elevated HE4 at relapse (or during 
follow-up), but elevated HE4 was also present in the control 
group of patients with no clinical detection of relapse.
A study by Plotti et al (27) investigated serum CA125 
and HE4 levels in 34 patients with radiological suspicion of 
recurrence and in 34 patients with benign ovarian tumors. 
The CA125 sensitivity and specificity for detecting recurrent 
ovarian cancer were 35.29 and 58.82%, respectively. The 
HE4 sensitivity values were 73.53 and 26.47% when using 
70 and 150 pmol/l cut‑offs, respectively. HE4 specificity was 
100% (all patients in the ovarian cancer group had relapse of 
ovarian cancer). When combining CA125 and HE4 at a cut-off 
of 70 pmol/l, the sensitivity in detecting recurrent ovarian 
cancer was 76.47% with a specificity of 100%. It is difficult to 
compare these results with the current study, since Plotti et al 
used a patient group with benign tumors for comparison and 
therefore likely achieved a higher specificity compared to the 
current results, for which the control group was ovarian cancer 
patients without recurrence during follow-up.
A relatively recent study by Manganaro et al (28) inves-
tigated three consecutive serum samples drawn at 3-month 
intervals from 21 patients with advanced ovarian cancer. In the 
9 patients with relapse, an increase in HE4 (>150 pmol/l) was 
noted in 22, 78 and 89% of the patients according to the time 
interval from surgery (1-3 months from surgery, 4-6 months 
and 7-10 months from surgery, respectively). Only 44% of 
the patients with relapse showed CA125 levels >35 U/ml at 
7-10 months from surgery. None of the 12 patients with stable 
disease had HE4 levels >150 pmol/l, whereas 4 patients had 
CA125 levels >35 U/ml. These results are in agreement with 
those of the current study, wherein the predictive value of HE4 
also increased with the time interval.
Only a few other studies, which have included ≤20 patients, 
have investigated HE4 during follow-up, with similar 
results (29-31).
All of the previous studies are substantially smaller than 
the current study and do not have a control group of a reason-
able number of patients without clinical recurrence/progressive 
disease. For certain of the studies, it is not clear when follow-up 
blood samples were taken, and some samples appear to be 
drawn during the chemotherapy. The material used in the 
present study was prospectively collected and retrospectively 
analyzed as part of a prospective marker protocol, and blood 
tests were recorded regularly during follow-up. The patients 
were not retrospectively identified, since their recurrence was 
already known, and a group of patients with no clinical relapse 
were available for marker comparison. We have previously 
published the dynamics of HE4 and CA125 during chemo-
therapy, and therefore this was not in the scope of the present 
study (32).
The largest of the previously described studies is the study 
by Plotti et al (27). As a criterion for inclusion, these patients 
had radiological signs of relapse at the time of serum sample 
collection. Therefore, the sample was drawn at time of diag-
nosis for recurrent disease and not as part of a follow-up study. 
The 100% specificity is obvious when all included patients 
had recurrent disease at sample collection. Furthermore, no 
comparisons with patients without relapse were performed, 
and only comparisons with a control group ~30 years younger 
than an average ovarian cancer cohort, and in which every 
individual had a benign ovarian tumor.
Early treatment of recurrence may not lead to an 
improved overall survival time based on therapies available 
at present (33). Nevertheless, the majority of ovarian cancer 
patients with advanced disease at diagnosis will relapse after 
primary treatment, with a dismal prognosis (34). Therefore, 
investigation of the level of serum markers in patients under 
monitoring may be essential in distinguishing patients at 
risk of relapse from those with less aggressive disease. HE4 
appears to be a sensitive and specific marker for the detection 
of recurrence and, in some cases, has the potential to detect 
recurrence in patients in whom CA125 is negative. However, 
based on the present results, investigating consecutive blood 
samples in comparison to a single blood test drawn at the time 
of diagnosis is not as simple as previously described in the 
literature. The picture also looks different when marker levels 
are compared with those of ovarian cancer patients without 
known relapse, instead of with a group of healthy women. 
What is clear from the current study and other studies is that 
there will be cases in which CA125 is not workable and in 
which HE4 may be a better marker of recurrence.
In conclusion, the results presented here indicate that an 
early increase of >50% of HE4 in the follow-up period relative 
to the EOT suggests a high risk of recurrence. This opens the 
perspective of early treatment. However, the results call for 
confirmation in a larger number of patient samples.
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